SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to a massive volume spike and price surge, triggering multiple trading halts, as community discussion focuses on its extremely low float and high insider ownership for a potential short squeeze. Many are comparing it to recent explosive SPACs, with speculative targets suggesting significant upside, fueled by talking points like a rumored "sex toy manufacturer" acquisition. The stock's momentum reflects its position as a key play in the current "SPAC mania" for micro-float tickers.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is rapidly trending due to a potent combination of its extremely low share float and a potential short squeeze, driving significant momentum. The recent announcement of a strategic manufacturing partnership, expected to boost production margins, further amplifies investor interest. The community is actively discussing strong buying defense and a "textbook" short squeeze play as the company continues to expand global adoption of its fingerprint drug screening technology.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings (ONDS) is trending due to recent autonomous system orders and the FCC's ban on foreign-made drones, which significantly boosts its role in the domestic market. The community is actively discussing a potential short squeeze and anticipating a significant price breakout, with many seeing dips as buying opportunities. This positions Ondas as a crucial player in the growing defense and critical infrastructure sectors for autonomous and counter-drone solutions.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending after the FDA issued a Complete Response Letter for its relacorilant hypertension indication, triggering a sharp stock decline and intense community debate. Investors are divided, with many viewing the sell-off as an overreaction given the company's existing profitable drug and other pipeline programs, while others express caution regarding potential delays and future prospects.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is trending following its recent FDA approval of NEREUS, the first new motion sickness treatment in over four decades, validating a significant pipeline asset. Community discussion highlights the drug's broader potential for GLP-1 induced nausea, fueling speculation of substantial upside, a potential short squeeze, and even a buyout, given the company's strong financial standing and additional upcoming regulatory catalysts.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending following its CEO's strategic insights on CNBC and news of spinning off its cloud business into ChronoScale, a move seen by many as unlocking significant value and clarifying its pure-play AI data center infrastructure focus. The community is actively discussing sustained demand from hyperscalers and strong analyst confidence ahead of its upcoming earnings report, fueling bullish sentiment despite recent price volatility. This strategic realignment aims to capitalize on the booming AI infrastructure market with a clearer business model and substantial contracted revenue.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst a wave of strong bearish sentiment, largely attributed to sustained selling pressure, high short interest, and year-end tax loss harvesting. The community is actively discussing the recent FDA approval of Novo Nordisk's oral Wegovy pill, seeing a potential for partnership and a significant catalyst for HIMS's future growth in GLP-1 offerings, alongside its ongoing expansion in D2C lab testing and international markets. Despite current frustration, many long-term investors are using this dip as a buying opportunity, anticipating a strong reversal.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after rival Corcept Therapeutics received an FDA Complete Response Letter for its Cushing's syndrome drug, effectively removing a near-term competitor for Xeris's Recorlev. The community is buzzing with bullish sentiment, emphasizing Recorlev's blockbuster potential and the significant undervaluation of XERS, further supported by advancing pipeline assets like XP-8121 and robust gross margins.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA's acceptance and priority review of its supplemental New Drug Application for AXS-05 in Alzheimer's disease agitation, with an action date anticipated in the near future. This significant regulatory milestone, combined with growing sales of its existing CNS therapies like Auvelity, has ignited immense optimism within the community, with many anticipating substantial long-term value and discussing breakthrough potential.

Motorola Solutions, Inc. engages in the provision of communication infrastructure, devices, accessories, software, and services. It operates through the Products and Systems Integration and Software and Services segments. The Products and Systems Integration segment includes a portfolio of infrastructure, devices, accessories, and video security devices, and the implementation and integration of such systems, devices, and applications. The Software and Services segment focuses on the public safety and enterprise Command Center Software, unified communications applications, and video software solutions. The company was founded on September 25, 1928 and is headquartered in Chicago, IL.

Motorola Solutions Inc

Motorola Solutions ($MSI) is trending following strategic acquisitions in advanced communications and AI-powered video monitoring, reinforcing its leadership in mission-critical technology for public safety and enterprise security. Community sentiment reflects a strong focus on institutional accumulation, evident in large dark pool trades and technical indicators suggesting the stock is oversold, signaling potential for a reversal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Kohl’s could announce the appointment on Monday, a day before the company’s third-quarter report.</li><li>The department store chain faces falling revenue and needs the CEO to offer long-term stability and direction.</li><li>For Q3, analysts expect the company’s revenue to continue to decline with a negative bottom line.</li></ul>Kohl's Corp’s shares will be in focus on Monday, after a report said the department store chain plans to make interim chief Michael Bender its permanent CEO.The decision could be announced as early as Monday, Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-11-23/kohl-s-to-name-michael-bender-as-ceo-after-year-of-disarray">reported</a> on Sunday, citing a person familiar with the matter. The company is scheduled to report its third-quarter results on Tuesday before the markets open.<h2 class="st-heading-2">Three CEOs In Four Years</h2>Bender was appointed the interim CEO in May after Kohl’s fired its then-CEO, Ashley Buchanan, for financial impropriety. Buchanan was found to have pushed for deals with a vendor with whom he had a personal relationship; he was in the CEO role for less than 100 days.Kohl’s has cycled through three CEOs in the past four years, underscoring the company’s need for a leader who can provide long-term stability and direction. Bender, who was earlier the CEO at Eyemart Express and also worked at Walmart and Victoria’s Secret, joined Kohl’s board in 2019.&nbsp;<h2 class="st-heading-2">Retail’s View</h2>On Stocktwits, retail sentiment for KSS remained ‘bearish’ as of late Sunday, unchanged from last week, while message volume stayed ‘low.’<figure class="image"><img style="aspect-ratio:637/73;" src="https://news.stocktwits-cdn.com/Screenshot_2025_11_24_at_7_19_09_AM_png_9d046b256d.webp" alt="Screenshot 2025-11-24 at 7.19.09 AM.png" width="637" height="73"><figcaption>KSS sentiment and message volume as of November 23 | Source: Stocktwits</figcaption></figure>“At least we now know what we got, going forward. A proven record,” said a user.&nbsp;<stembedurl>https://stocktwits.com/Equity30/message/637214164</stembedurl>“$KSS lets get this puppy trending again. Expecting lots more good news from Kohl's this week,” remarked another, a likely reference to expectations from the company’s upcoming earnings report.<stembedurl>https://stocktwits.com/Equity30/message/637224188</stembedurl><h2 class="st-heading-2">Earnings Expectations</h2>Analysts expect Kohl’s revenue to decline 4% to $3.39 billion, according to Koyfin. That would be the lowest pace of decline since the January 2024 quarter. Adjusted loss per share is expected to be $0.17, compared to a $0.20 per share adjusted profit in the year-ago quarter.Kohl's results will likely show a sequential acceleration in sales trends, though it is expected to offer a cautious outlook, analysts at UBS said in an investor note earlier this month. Citi had opened an "upside 90-day catalyst watch" on the shares last month.Kohl’s earnings come amid mixed results from major retailers: Walmart, thanks to its pole position, showed continued momentum, while Target’s sales shrank, prompting the company to cut its full-year profit forecast. Walmart, Target, and other consumer retail companies have flagged weak consumer spending among low-income consumers.As of the last close,&nbsp;<a href="https://stocktwits.com/symbol/KSS">Kohl’s stock</a> is up 11% year–to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Kohl'scorporate logo is displayed on a sign at their store on January 31, 2025 in San Diego, California. (Photo by Kevin Carter/Getty Images)

Kohl’s Plans To Name Michael Bender Permanent Chief Exec After Cycling Through 3 CEOs In Four Years: Report

Bender was appointed the interim chief executive in May after the then-CEO Ashley Buchanan was fired for financial impropriety.

Equity

Will Small-Cap ETFs be Able to Sustain the New-Found Optimism? 

IWM jumped 6.3% in a month (as of Sept. 3, 2025), outpacing SPY, as Fed rate cut hopes and strong value ETF gains fueled small-cap momentum. Will the rally last?

Kohl’s (KSS) shares jumped 13.5% at Thursday’s open following the release of first-quarter results that showed a significantly smaller loss than analysts had anticipated, and reaffirmed its full-year guidance.The department store chain reported a diluted loss per share of $0.13, narrower than the expected loss of $0.22, as per Koyfin data.&nbsp;Its revenue decreased 4.1% year-over-year (YoY) to $3.05 billion, missing Wall Street’s estimate of $3.06 billion by a whisker. Comparable sales were down 3.9% as compared to the previous year.&nbsp;“Our first quarter performance was ahead of our expectations, and the actions we are taking are starting to make progress with early signs of a positive impact,” said interim CEO Michael Bender, marking his quarterly earnings debut.Bender took over after Kohl’s fired former CEO Ashley Buchanan earlier this month, just four months into his tenure, for trying to steer business to his romantic partner, Chandra Holt. The company&nbsp;stated that Buchanan did not disclose the relationship as required by its ethics policy and deemed his actions&nbsp;to be cause for dismissal.During the first quarter (Q1), gross margin as a percentage of net sales rose by 37 basis points to 39.9%. Selling, general, and administrative (SG&amp;A) expenses declined 5.2% year-over-year to $1.2 billion, representing 36.0% of total revenue, a decrease of 32 basis points.Operating income increased to $60 million from $43 million in the prior year, equivalent to 1.9% of total revenue.&nbsp;The company reported a net loss of $15 million,&nbsp;an improvement from the $27 million net loss in the previous year. Inventory rose 2% YoY to $3.1 billion. Operating cash flow was negative $92 million.For the full year 2025, the company continues to expect net sales to decline between 5% and 7%, with comparable sales decreasing between 4% and 6%.&nbsp;Operating margin is projected to range from 2.2% to 2.6%, while diluted earnings per share are expected to fall between $0.10 and $0.60.&nbsp;Capital expenditures are forecasted to be between $400 million and $425 million.&nbsp;<a href="http://stocktwits.com/symbol/KSS">Kohl’s stock</a> has fallen 35% this year, and more than 65% over the past 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kopin-cfo-rich-sneider-to-retire-after-25-years/ch0AYq5RbtY">Kopin CFO Rich Sneider To Retire After 25 Years</a>

Kohl’s Stock Jumps On Q1 Earnings Beat, Reaffirmed Guidance

 For the full year 2025, the company continues to expect net sales to decline between 5% and 7%, with comparable sales decreasing between 4% and 6%. 

Should Invesco S&P SmallCap 600 Revenue ETF (RWJ) Be on Your Investing Radar?

Xerox Corp. (XRX), which sells print and digital document products, and services globally, reported Tuesday ahead of the market open mixed quarterly results but retail remains optimistic.The Norwalk, Connecticut-based company reported fiscal 2024 fourth-quarter adjusted earnings per share (EPS) of $0.36, down from last year’s $0.43 and missing the consensus estimate of $0.53, as seen on Koyfin.Revenue fell 8.6% year-over-year (YoY) to $1.61 billion versus the $1.58 billion consensus estimate. Print and other revenue fell 8.7% to $1.54 billion and Xerox Financial Services (XFS) revenue declined 11% to $89 million.Xerox’s bottom line and topline trailed expectations in the past four quarters.Fourth-quarter adjusted operating margin climbed 100 basis points (bps) to 6.4%, and operating cash flow fell $182 million YoY to $467million.CEO Steve Bandrowczak said, “2024 was a critical year as we implemented a new operating model and structural process improvements to position Xerox for long-term, sustainable growth.’’Looking ahead, the company expects low-single-digit revenue growth in constant currency for fiscal year 2025 and free cash flow of $350 million to $400 million. Analysts, on average, expect reported revenue of $6.36 billion, marking a 2.25% YoY increase.Bandrowczak said, “We continue to see steady progress in our Reinvention, reflecting the resilience of our team and initiatives taken to-date.”“In 2025, we expect to build on changes made in 2024 in order to focus on executing our Reinvention strategy, realizing the benefits of the ITsavvy and pending Lexmark acquisitions, and strengthening our balance sheet.’’<figure class="image"><img style="aspect-ratio:641/137;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/xrx_sentiment_24e75beb49.png" alt="xrx-sentiment.png" width="641" height="137"><figcaption>&nbsp;XRX sentiment and message volume January 28, as of 9:08 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, sentiment toward<a href="https://stocktwits.com/symbol/XRX/earnings"> Xerox stock</a> turned to ‘extremely bullish’ (80/100) from the ‘neutral’ (50/100) mood that prevailed a day ago. Retail chatter perked up amid the earnings release with the message volume hitting ‘extremely high’ levels.Xerox shares fell 3.60% to $9.36 in premarket trading. The stock has gained over 15% in January after declining over 42% in 2024.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/soundhhound-ai-stock-sinks-on-capital-raise-plans/chbVdwBRYK">SoundHound AI Stock Sinks On Plan To Raise $500M Through Securities Offerings: Retail Stays Bearish</a>

 2018/12/04: In this photo illustration, the Xerox Corporation logo is displayed on a smartphone. 

Xerox Stock Slips Premarket After Mixed Q4 Results But Retail Mood Brightens 

Xerox CEO said, “2024 was a critical year as we implemented a new operating model and structural process improvements to position Xerox for long-term, sustainable growth.”

RWJ
Invesco S&P SmallCap 600 Revenue ETF

Feed

News

Sentiment

Fundamentals

Info

Latest RWJ News

RWJInvesco S&P SmallCap 600 Revenue ETF